WORK PLATFORMS

  • 4 self sustained, interlinked, mutually soportive, and synergic platforms of integrative work.

 

  • Each work platform is itself a collaboration of all laboratories of our network, bringing together multiple competences.

 

BEDSIDE TO BENCH AND BACK APPROACH

WP1: SELECTING CLINICALLY RELEVANT MOLECULAR TARGETS OF NEUROPATHIC PAIN

1.1 SENSORY PROFILES IN HUMAN SUBJECTS

SMALL FIBER NEUROPATHY
NEUROMAS
SENSORY PROFILE

1.2 IDENTIFICATION OF MOLECULAR TARGETS

EXPECTED RESULTS:

Correlation between sensory profiles and a set of key molecular targets for WP2.

 

 

MOLECULAR BIOLOGY / HISTOLOGY
CONTROL / NEUROPATHY

WP2: SENSORY TRANSDUCTION AND EXCITABILITY CHANGES

2.1 EXPRESSION PROFILE IN PAIN MODELS

2.2 PHARMACOLOGICAL MODULATION

2.3 GENE THERAPY USING AAV VECTORS

EXPECTED RESULTS:

Restore excitation/inhibition balance using pharmacological and gene therapy strategies.

 

 

WP3: POST-TRANSLATIONAL MODIFICATIONS IN NEUROPATHIC PAIN

3.1 CDK5 ACTIVITY IN NEUROPATHIC PAIN MODELS

3.2 PHOSPHORYLATION OF CDK5 TARGETS IN NEUROPATHIC PAIN MODELS

EXPECTED RESULTS:

Cdk5 increases peripheral and central pain sensibilization.

 

 

WP4: BACK TRANSLATING PRECLINICAL RESULTS TO HUMANS

4.1 ELECTROPHYSIOLOGY FROM HUMAN TISSUES

EX VIVO PREPS
PHARMACOLOGY

4.2 HUMAN SENSORY NEURONS FROM STEM CELLS

EXPECTED RESULTS:

Validation of mouse models findings in human ex-vivo preparations.

 

INDUCED INJURY